Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02328417
Other study ID # PRO-RAC
Secondary ID
Status Completed
Phase N/A
First received November 18, 2014
Last updated February 21, 2018
Start date December 2014
Est. completion date December 2017

Study information

Verified date February 2018
Source Hospital Universitario Fundación Alcorcón
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Prospective non randomized study of two cohorts: usual protocol and the application of accelerated recovery protocol. F/up after discharge, 90 days and thereafter according to protocol of each center. Compliance to be assessed.


Description:

This is a prospective non randomized study of two cohorts, one defined by the usual protocol and the other one by the application of accelerated recovery protocol. It's discarded a priori a prospective randomized trial, since it does not seem feasible to avoid byass of control group when synchronizing the active intervention and control. Subjects surgery will be followed after discharge for a minimum of 90 days, and thereafter according to protocol of each center. Patients will be provided with a satisfaction survey 90 days after surgery.

The degree of compliance with the protocol will be assessed through a checklist indicating compliance with each of the steps of the protocol in both groups. All patients will sign an informed consent for the study authorizing the use of their clinical data for statistical analysis.


Recruitment information / eligibility

Status Completed
Enrollment 241
Est. completion date December 2017
Est. primary completion date February 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Consecutive patients scheduled for radical cystectomy in the participating hospitals

- Signed informed consent

Exclusion Criteria:

- Refusal to sign informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Consecutive radical cystectomies
Pre-, intra- and post-operative clinical measures during radical cystectomy clinical process

Locations

Country Name City State
Spain Hospital Universitario Principe de Asturias Alcalá de Henares Madrid
Spain Hospital Universitario Fundación Alcorcón Alcorcón Madrid
Spain Hospital Universitario de Getafe Getafe Madrid
Spain Hospital Universitario Severo Ochoa Leganés Madrid
Spain Fundación Jiménez Díaz Madrid
Spain Hospital Doce de Octubre Madrid
Spain Hospital Infanta Leonor Madrid
Spain Hospital Universitario Gregorio Marañon Madrid
Spain Hospital Puerta de Hierro Majadahonda Madrid
Spain Hospital Universitario Rey Juan Carlos Móstoles Madrid
Spain Hospital Universitario de Torrejón Torrejón de Ardoz Madrid
Spain Hospital Universitario Infanta Elena Valdemoro Madrid

Sponsors (1)

Lead Sponsor Collaborator
Carlos Llorente

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary In-hospital length-of-stay (LOS), defined as the number of days since the admission of the patient to the hospital until the day of discharge, Morbidity of surgery. Categorized by the Clavien complications scale at 30-, 60- and 90-postoperative days Day 1: Admission to the hospital Last day of accountant: Discharge from the hospital or death in the hospital. 5-40 days
Secondary Mortality at 30-, 60- and 90- postoperative days 90 days
Secondary 30-day readmission rate 30 days
Secondary Transfusion rate 90 days
Secondary Patient satisfaction measured with the enclosed questionnaire Do you know the names of your attending physician and nurse?
The quality of the preoperative care and information has been:
The quality of the postoperative care and information has been:
Do you think that the information on the care of your urostomy has been enough? Yes/No If NO, on which of the following points would you have liked receiving more information? Types of collecting bags and accessories Stomal hygiene and change of bags Complications of the stoma and the surrounding skin Counseling on food habits, dress apparel, and physical and sexual activity Comunity counselling: Stoma therapist, patients associations If you had a neobladder performed, were you trained in self-catheterization ? How would you rate your motivation in learning the above mentioned issues?
In all, the quality of the health care that you have received is:
90 days
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06034015 - A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers Phase 1
Recruiting NCT04235764 - En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
Completed NCT02371447 - VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer Phase 1/Phase 2
Recruiting NCT04081246 - Transurethral Modified En Bloc Resection For Large Bladder Tumours. N/A
Recruiting NCT06059547 - Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer Phase 2
Terminated NCT04779489 - Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer N/A
Not yet recruiting NCT04493489 - Propranolol Adjuvant Treatment of Bladder Cancer Phase 2
Completed NCT03520231 - Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases Phase 2
Recruiting NCT04537221 - Nordic Cystectomy Study III - Transfusion
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Completed NCT01955408 - Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment N/A
Completed NCT04487457 - Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Recruiting NCT05562791 - A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer Phase 1
Completed NCT00199849 - NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine Phase 1
Completed NCT02781428 - To Detect the Sensitivity of the UroMark Assay
Recruiting NCT04738630 - Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer Phase 2
Completed NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2
Active, not recruiting NCT03978624 - Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer Phase 2
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A